GlassScriptPhysician profile
Jeffery A Trail
NPI 1578542486
$12,155.05
in general payments reported to CMS, 2019-2025
61 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,639 · 2020: $1,444 · 2021: $2,185 · 2022: $1,325 · 2023: $1,905 · 2024: $1,843 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,503 · Education: $58.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,503.10 |
| Education | $58.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.81 | 2019-2025 | Qulipta, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,359.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,190.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $945.91 | 2019-2025 | |
| Amgen INC. | $902.89 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $629.05 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $596.90 | 2019-2024 | Xarelto, Spravato |
| Kowa Pharmaceuticals America, INC. | $400.29 | 2022-2025 | Zoryve, Livalo, Seglentis |
| Glaxosmithkline, LLC. | $323.56 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $312.77 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $306.79 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.18 | 2019-2024 | Jardiance, Ofev |
| Sanofi-Aventis U.S. LLC | $279.78 | 2019-2023 | |
| Allergan, INC. | $214.42 | 2019-2020 | |
| Corcept Therapeutics | $180.22 | 2023-2025 | Korlym |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Trail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.